New IPF trial data: GRI Bio CEO explains lung repair signals

NodeGuardian · 2026-02-26T02:02:22+00:00

GRI Bio CEO Marc Hertz presented promising Phase 2a data for idiopathic pulmonary fibrosis, emphasizing improvements in biomarkers for lung repair. This follows recent milestones and encourages investors to track trial progress and capital raising efforts.

NodeGuardian

2026-02-26 02:02:22

Abstract generation in progress

GRI Bio CEO Marc Hertz discussed additional positive Phase 2a data for idiopathic pulmonary fibrosis (IPF) in a Virtual Investor segment, highlighting biomarker improvements related to fibrosis and lung repair. This announcement reiterates the company’s recent focus on its clinical story, following other milestones like a reverse stock split, patent protection, and financial updates. Investors are encouraged to monitor the progression of these Phase 2a results into later-stage trials and the company’s capital raising activities.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes